Skip to main content

Advertisement

Table 1 Characteristics of 61 patients, by group according to occurrence of late-onset neutropenia during follow-up

From: Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab

  Total (n = 61) LON (n = 11) Non-LON
(n = 50)
P value
Age at rituximab start, years, mean (SD), range 57.3 (16.4), 18–85 58.9 (18.2), 29–82 57.0 (16.2), 18–85 0.73
Female sex, % 75.4 72.7 76.0 0.82
Disease characteristics
 Diagnosis     0.82
  SLE, % 23.0 27.3 22.0  
  AAV, % 21.3 27.3 20.0
  RA-seropositive, % 37.7 36.4 38.0
  RA-seronegative, % 18.0 9.1 20.0
  Disease duration, years, median (IQR) 7.0 (3.0–13.0) 4.0 (2.0–11.0) 7.5 (3.0–13.3) 0.43
 Previous treatments
  Number of DMARDs, mean (SD), range 3.6 (1.8), 0–8 4.1 (2.1), 1–8 3.5 (1.8), 0–7 0.27
  Cytotoxics and biologics, % 63.9 81.8 60.0 0.30
  Prednisolone, % 98.4 100 98.0 1.0
 Major indication for rituximab, by manifestations 0.15
  Arthritis and dermatologic, % 59.0 45.5 62.0  
  Renal, % 19.7 9.1 22.2
  Pulmonary and ENT, % 16.4 27.3 14.0
  Neurologic, % 3.3 9.1 2.0
  Hematologic, % 1.6 9.1 0
 Rituximab regimens     0.84
  375 mg/m2 weekly for 4 weeks, % 14.8 9.1 16.0  
  1 g twice 2 weeks apart, % 59.0 63.6 58.0
  0.5 g twice 2 weeks apart, % 26.2 27.3 26.0
 Concurrent DMARDs
  Any DMARDs, % 78.7 72.7 80.0 0.69
  Cyclophosphamide, % 21.3 27.3 20.0  
  Azathioprine, % 9.8 9.1 10.0
  Mycophenolate mofetil, % 8.2 9.1 8.0
  Methotrexate, % 34.4 9.1 40.0
  Concurrent prednisolone, % 88.5 100 86.0 0.33
  1. The p values refer to the comparisons between LON and non-LON groups. Cytotoxics used were cyclophosphamide and chlorambucil
  2. Abbreviations: LON Late-onset neutropenia, SLE Systemic lupus erythematosus; AAV Antineutrophil cytoplasmic antibody-associated vasculitis, RA Rheumatoid arthritis, DMARDs Disease-modifying antirheumatic drugs, ENT Ear, nose, throat